Rapiscan Diagnostic's Safety Update: Stroke and Seizure Risks

Rapidscan Pharma Solutions EU Ltd. has issued a safety communication detailing potential risks of stroke and epileptic seizures following the administration of its diagnostic agent, Rapiscan® (regadenosone).

The drug, regadenosone, is a selective adenosine receptor agonist used to simulate pharmacologically the effects of exercise in myocardial perfusion imaging. It enhances blood flow in the coronary arteries, aiding the identification of poorly perfused areas of the heart muscle, particularly in patients unable to undergo physical stress testing.

The safety update notes that instances of increased blood pressure, severe hypotension, worsening atrial fibrillation, and strokes have been reported post-administration. The company advises that the use of regadenosone should be considered with caution in patients with uncontrolled hypertension, potentially delaying administration. It should not be used in patients with severe hypotension. Caution is also advised for those with a history of atrial fibrillation or a risk of severe hypotensive events.

Furthermore, the communication clarifies that aminophylline, a xanthine derivative that can be used to antagonize severe or persistent side effects, is not recommended for terminating regadenosone-induced seizures. Reports suggest aminophylline may prolong the duration of these seizures and possesses pro-convulsant properties itself.

The product information for Rapiscan® has been updated to incorporate these new safety guidelines.